BioMarin Pharmaceutical Inc.
BMRN
$58.58
$0.510.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.92% | 14.84% | 15.65% | 28.28% | 19.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.92% | 14.84% | 15.65% | 28.28% | 19.61% |
| Cost of Revenue | -0.91% | -6.02% | -1.30% | 47.18% | 2.03% |
| Gross Profit | 29.22% | 36.46% | 20.24% | 22.94% | 38.46% |
| SG&A Expenses | -11.69% | -8.76% | -34.19% | 17.48% | 27.62% |
| Depreciation & Amortization | -66.11% | -66.10% | -36.66% | -68.06% | -8.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.28% | -8.61% | -20.82% | 14.71% | 11.68% |
| Operating Income | 129.87% | 185.35% | 842.98% | 273.11% | 83.71% |
| Income Before Tax | 125.43% | 125.58% | 777.73% | 222.64% | 86.61% |
| Income Tax Expenses | 129.69% | 210.35% | 4,364.89% | 2,096.82% | 69.00% |
| Earnings from Continuing Operations | 124.43% | 109.43% | 513.22% | 162.72% | 91.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.43% | 109.43% | 513.22% | 162.72% | 91.25% |
| EBIT | 129.87% | 185.35% | 842.98% | 273.11% | 83.71% |
| EBITDA | 101.10% | 132.45% | 418.73% | 136.43% | 61.47% |
| EPS Basic | 122.35% | 107.14% | 506.11% | 159.72% | 89.03% |
| Normalized Basic EPS | 123.32% | 146.43% | 1,257.41% | 218.79% | 84.46% |
| EPS Diluted | 124.28% | 108.02% | 644.69% | 160.67% | 87.65% |
| Normalized Diluted EPS | 129.33% | 152.72% | 1,239.68% | 212.92% | 81.45% |
| Average Basic Shares Outstanding | 0.94% | 1.11% | 1.17% | 1.17% | 1.15% |
| Average Diluted Shares Outstanding | -1.70% | -1.40% | 2.47% | 3.12% | 2.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |